ClinicalTrials.gg
RecruitingNCT07442903TRIC-I-HF 2Updated May 8, 2026

TRICuspid Intervention and Invasive Hemodynamic Monitoring in Heart Failure

An interventional study of Pulmonary artery sensor system in Heart Failure With Severe Tricuspid Regurgitation, sponsored by LMU Klinikum. Recruiting at 2 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-08.

Sponsored by LMU Klinikum · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 600 studies in Heart Failure with a site in Germany — 105 open to participants now, 136 under way, 19 of them phase 3. Heart Failure · Germany.

Planned enrollment
290th of 386
45 · median 161
Started
2026
with 20 others
No phase
175 of 600
37 open now
Primary completion
2029-03
later than 107 of 135 live
Registered
579th of 600
by date

Among the 600 studies in Heart Failure with a site in Germany, this one is the 290th largest by planned enrollment of the 386 interventional ones that give a count, is one of 21 that started in 2026, is one of 175 with no phase, reaches primary completion later than 107 of the 135 other live ones, and was the 579th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

105 of the 600 studies in Heart Failure with a site in Germany are open now. Recruiting first, the newest first:

99 more — sign in →

All 105 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 600 studies in Heart Failure with a site in Germany, or all of them as a file.
02

Study summary

Tricuspid regurgitation (TR) is a severe and highly prevalent disease that leads to right-sided heart failure. The severity of TR is associated with increasing morbidity and mortality. While severe TR and right-sided heart failure have an impact on the quality of life and prognosis of the individual patient, repeat heart failure hospitalizations challenge limited hospital resources on an institutional level and stress the medical health care system on an economic level. Transcatheter valve interventions (TTVI) including transcatheter tricuspid edge-to-edge repair (T-TEER) and transcather tricuspid valve replacement (TTVR) have been established as effective techniques to safely reduce TR severity in many patients leading to significant improvements in quality-of-life and potential reduction of heart failure hospitalizations. However, the rate of heart failure hospitalizations remains elevated, despite technically successful TTVI. Accordingly, heart failure hospitalizations occur in approximately 15-20% of patients and often result in complicated and prolonged in-hospital treatments. Therefore, optimization of the heart failure management and reduction of post-procedural heart failure hospitalizations are unmet needs in patients after TTVI.

Implantable pulmonary artery (PA) pressure sensing (IPAPS) is a novel strategy to improve heart failure management and to reduce heart failure hospitalizations. Continuous PA pressure monitoring provides an early indication of worsening heart failure trends and allows for the guidance of medical management to prevent unplanned hospitalizations. So far, this technology has been predominantly studied in patients with left-sided heart failure. The performance of PA pressure monitoring in right-sided heart failure is understudied. Also, the changes of PA pressure levels in response to TTVI has not yet been investigated. Heart failure hospitalizations in patients with right-sided heart failure are caused by gradual fluid overload resulting in shortness of breath, weight gain, peripheral edema, and ascites. Fluid overload will lead to a simultaneous increase of PA pressure, and therefore, may also be identified early by IPAPS in right-sided heart failure patients. The Cordella PA Sensor System has been designed for multi-parametric heart failure telemonitoring including PA pressure and other vital signs. In clinical trials, the Cordella PA Sensor System demonstrated a significantly lower heart failure hospitalization and all-cause mortality event rate in NYHA class III heart failure patients, when compared to historical PA pressure studies. IPAPS was associated with significant improvements in quality-of-life metrics, while complication rates were low. The Cordella PA Sensor System is expected to receive CE-marking in 2025. The proposed study will be initiated after CE-mark approval, so that all patients will be treated with CE-marked devices and on-label.

In this study we will assess the applicability of PA pressure monitoring using the Cordella Sensor device in patients with severe TR undergoing T-TEER or TTVR (n=30 patients). Included patients will undergo right-heart catheterization for evaluation of TR as indicated by clinical routine practice before TTVI. During right heart catheterization, patients receive implantation of the Cordella Sensor device. Thereafter, PA pressure will be monitored for approximately 4 weeks prior to TTVI. Subsequently, patients undergo T-TEER or TTVR as indicated and recommended by the heart team. PA pressure telemonitoring will be continued after TTVI. The change in PA pressure before TTVI compared to the first month after TTVI will be reported as primary endpoint in this pilot study. The performance of the Cordella PA Sensor System in right-sided heart failure patients for remote heart failure monitoring will be assessed over a 12-month follow-up period as the main secondary endpoint.

The concept of IPAPS has the potential to significantly improve the post-procedural heart failure management in patients after TTVI. The proposed pilot study will serve as base for the development of a larger clinical trial evaluating the concept of PA telemonitoring for improving outcomes in patients with severe tricuspid regurgitation and right-sided heart failure.

In an adjunct feasibility study, an implantable pulmonary artery pressure sensor (IPAPS) will be implanted off-label in the hepatic vein to evaluate a sensitive heart failure monitoring strategy in patients with right-sided heart failure (n = 15).

03

Conditions studied

  • Heart Failure With Severe Tricuspid Regurgitation

Keywords

  • Heart failure
  • Tricuspid regurgitation
  • Transcatheter tricuspid intervention
  • PA sensor
  • Remote hemodynamic management
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • Heart-failure class III despite optimal medical therapy
  • Heart failure related hospitalization in the 12 month prior to Cordella PA pressure sensor system implant
  • Planned tricuspid transcatheter edge-to-edge repair (T-TEER) or transcatheter tricuspid valve replacement (TTVR)
  • Willingness to participate and sign
  • Ability to perform PA pressure reading and telemonitoring

Exclusion criteria

Exclusion Criteria:

  • Cardiogenic shock or hemodynamic instability
  • Previous tricuspid intervention or surgery with repair or replacement of tricuspid leaflets
  • Active endocarditis
  • Tricuspid valve stenosis (baseline tricuspid valve in-flow gradient > 5 mmHg)
  • of less than 12 months
  • Chronic renal failure requiring dialysis
  • Anatomic conditions impeding implantation of PA sensor
  • Acute pulmonary embolism or chronic thromboembolic pulmonary Hypertension (CTEPH)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    Patient scheduled for tricuspid intervention

    Implantation of pulmonary artery sensor system before tricuspid intervention

    Device: Pulmonary artery sensor system

Interventions

  • DevicePulmonary artery sensor system

    PA pressures will be monitored before and after TTVI by CE-certified PA Sensor System

06

What researchers measure

Primary outcomes

  1. Change in implantable pulmonary artery (PA) pressure sensing (IPAPS) before TTVI compared to one month after TTVI

    Time frame: 1 month post tricuspud intervention

Secondary outcomes

  1. All-cause mortality

    Time frame: 1, 6, and 12 months after TTVI

  2. Heart failure hospitalizations

    Time frame: 1, 6, and 12 months after TTVI

  3. Days alive out of hospital at 12 months

    Time frame: 1, 6, and 12 months after TTVI

  4. Change in echocardiographic parameters, in specific TR grade

    Time frame: 1, 6, and 12 months after TTVI

  5. Change in laboratory markers for cardiac function, pro-BNP value

    Time frame: 1, 6, and 12 months after TTVI

  6. Change in laboratory markers for renal function, eGFR value

    Time frame: 1, 6, and 12 months after TTVI

  7. Change in laboratory markers for hepatic function, bilirubin value

    Time frame: 1, 6, and 12 months after TTVI

  8. Myocardial infarction, pulmonary embolism, and stroke

    Time frame: 1, 6, and 12 months after TTVI

  9. Bleeding events according to VARC classification

    Time frame: 1, 6, and 12 months after TTVI

  10. Change of diuretic drugs and heart failure medications

    Time frame: 1, 6, and 12 months after TTVI

  11. Patient adherence to IPAPS (frequency of transmissions)

    Time frame: 1, 6, and 12 months after TTVI

  12. Change in IPAPS at 6, and 12 month post TTVI compared to baseline before TTVI

    Time frame: 1, 6, and 12 months after TTVI

  13. Changes of IPAPS in association to clinical improvement post TTVI (NYHA class, physical activity, 6-MWDT, QoL)

    Time frame: 1, 6, and 12 months after TTVI

07

Study locations

1 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Mar 2029, 37 months after the start.

Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 37 months is above that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2026
First posted
Mar 2, 2026
StartActual
Feb 17, 2026
Primary completionEst.
Mar 2029
CompletionEst.
Mar 2029
Last update
May 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07442903
Lead sponsor
LMU Klinikum
Responsible party
Thomas Stocker (Prof. Dr., LMU Klinikum) — Principal investigator
First posted
Mar 2, 2026
Start date
Feb 17, 2026
Primary completion
Mar 2029 (estimated)
Completion
Mar 2029 (estimated)
Last update
May 8, 2026

Study contacts

Thomas Stocker, MD
Contact
thomas.stocker@med.uni-muenchen.de
+498944000

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion